Global Diltiazem Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Diltiazem Market Insights, Forecast to 2034
Diltiazem is a nondihydropyridine (non-DHP) calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia. It relaxes the smooth muscles in the walls of arteries, which opens (dilates) the arteries, allows blood to flow more easily, and lowers blood pressure. Additionally, it lowers blood pressure by acting on the heart itself to reduce the rate, strength, and conduction speed of each beat.
Global Diltiazem market is expected to reach to US$ 354 million in 2024, with a positive growth of %, compared with US$ 336 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Diltiazem industry is evaluated to reach US$ 505 million in 2029. The CAGR will be 6.1% during 2024 to 2029.
Globally, Diltiazem key manufacturers include Bausch Health, Teva, Mylan, Athenex, Pfizer, Akorn, Sandoz, Sun Pharma and Hikma Pharmaceuticals, etc. Bausch Health, Teva, Mylan are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Diltiazem were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Diltiazem market and estimated to attract more attentions from industry insiders and investors.
Diltiazem can be divided into Tablet, Capsule and Injection,, etc. Tablet is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Diltiazem is widely used in various fields, such as Angina and Hypertension, etc. Angina provides greatest supports to the Diltiazem industry development. In 2022, global % sales of Diltiazem went into Angina filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Diltiazem market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Diltiazem market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

Bausch Health
Teva
Mylan
Athenex
Pfizer
Akorn
Sandoz
Sun Pharma
Hikma Pharmaceuticals
Zydus Pharmaceuticals
Par Pharmaceutical
Segment by Type
Tablet
Capsule
Injection
Angina
Hypertension
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Diltiazem plant distribution, commercial date of Diltiazem, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Diltiazem introduction, etc. Diltiazem Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Diltiazem
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Diltiazem market is expected to reach to US$ 354 million in 2024, with a positive growth of %, compared with US$ 336 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Diltiazem industry is evaluated to reach US$ 505 million in 2029. The CAGR will be 6.1% during 2024 to 2029.
Globally, Diltiazem key manufacturers include Bausch Health, Teva, Mylan, Athenex, Pfizer, Akorn, Sandoz, Sun Pharma and Hikma Pharmaceuticals, etc. Bausch Health, Teva, Mylan are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Diltiazem were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Diltiazem market and estimated to attract more attentions from industry insiders and investors.
Diltiazem can be divided into Tablet, Capsule and Injection,, etc. Tablet is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Diltiazem is widely used in various fields, such as Angina and Hypertension, etc. Angina provides greatest supports to the Diltiazem industry development. In 2022, global % sales of Diltiazem went into Angina filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Diltiazem market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Diltiazem market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
Bausch Health
Teva
Mylan
Athenex
Pfizer
Akorn
Sandoz
Sun Pharma
Hikma Pharmaceuticals
Zydus Pharmaceuticals
Par Pharmaceutical
Segment by Type
Tablet
Capsule
Injection
Segment by Application
Angina
Hypertension
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Diltiazem plant distribution, commercial date of Diltiazem, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Diltiazem introduction, etc. Diltiazem Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Diltiazem
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
